Advertisement Chinese Regulatory Changes for Human Serum and Plasma Exports Trigger Potential Delays - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Whitepapers

Chinese Regulatory Changes for Human Serum and Plasma Exports Trigger Potential Delays

Researchers conducting or planning to conduct clinical trials in China should be aware of new regulatory changes that specifically affect export shipments of human serum and plasma from China and the delays that the new administrative process may create. This free white paper includes a list of these major changes associated with the new regulations.